Antiviral Drugs - Estonia

Estonia

The projected revenue for the Antiviral Drugs market in Estonia is estimated to reach US$10.74m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 1.93%, leading to a market volume of US$11.82m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue of US$30,640.00m in 2024.
Estonia's growing demand for antiviral drugs is driven by a proactive healthcare system and a high level of public awareness about preventive measures.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand worldwide since the outbreak of the COVID-19 pandemic. Estonia, being a small country in Northern Europe, has also seen a surge in the demand for these drugs.

Customer preferences: The customers in Estonia have been more inclined towards purchasing antiviral drugs that have proven to be effective against COVID-19. The demand for these drugs has been high since the outbreak of the pandemic.

Trends in the market: The antiviral drugs market in Estonia has seen a significant increase in demand since the outbreak of the COVID-19 pandemic. The market has been growing at a steady pace, and the trend is expected to continue in the coming years. The demand for antiviral drugs has been driven by the need to combat viral infections, including COVID-19.

Local special circumstances: Estonia has a well-established healthcare system, which has been instrumental in the efficient distribution of antiviral drugs. The country has also been proactive in implementing measures to combat the spread of COVID-19, which has helped in reducing the number of cases.

Underlying macroeconomic factors: The Estonian economy has been growing steadily in recent years, which has led to an increase in disposable income. This has resulted in an increase in the demand for healthcare products, including antiviral drugs. Additionally, the Estonian government has been investing in the healthcare sector, which has helped in the development of new drugs and the expansion of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.